Phase 3 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have moderately severe or severe non-proliferative diabetic retinopathy (a specific stage of eye disease caused by diabetes) where certain eye treatments can safely be delayed for at least 6 months from the first screening visit
- People whose vision in the study eye is 20/40 or better (as measured by a standard eye chart test) at the first screening visit
- People who have diabetic retinopathy caused by Type 1 or Type 2 diabetes, with a blood sugar control reading (HbA1c) below 12% taken within the 60 days before the first screening visit
Who may not be able to join:
- People whose study eye shows active swelling at the centre of the retina (diabetic macular edema) above a certain thickness level, as measured by a specialised eye scan
- People who have active inflammation or infection in or around either eye at the time of the screening visits
- People who have abnormal blood vessel growth in the eye from a cause other than diabetes
- People who have previously had laser treatment to the retina (panretinal photocoagulation or similar)
- People who have received injections into the eye (such as anti-VEGF or steroid treatments) within the past 6 months, or who have had more than 10 such injections in the past 36 months
- People who have started an intensive insulin treatment programme (such as an insulin pump or multiple daily injections) within the past 6 months, or who plan to do so within 52 weeks after the trial starts
- People who have started a medication containing a GLP-1 receptor agonist (a type of diabetes medicine) within the 3 months before the first screening visit, or who plan to do so within 52 weeks after the trial starts
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase 2B: Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye; Phase 3: Percentage of Participants Achieving >= 2-Step Improvement from Baseline in Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye; Bilateral Portion: Bilateral portion: Number of participants experiencing ocular Adverse Events (AEs), Serious Adverse Events (SAEs), or any Adverse Events of Special Interest (AESIs); Bilateral Portion: Participants Who Experience Intraocular Inflammation; Bilateral Portion: Participants Who Experience Sc...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.